Treatment potential for immunotherapy-induced cytokine release syndrome
Drug Discovery World
JANUARY 18, 2024
Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS). POLB 001 demonstrated efficacy in reducing cancer immunotherapy-induced CRS in an in vivo animal model with CRS symptoms significantly improved following administration of POLB 001.
Let's personalize your content